@Article{or.2025.061120,
AUTHOR = {ALEX A. FRANCOEUR, NATALIE AYOUB, DANIELLE GREENBERG, KRISHNANSU S. TEWARI},
TITLE = {Drug discovery in advanced and recurrent endometrial cancer: Recent advances},
JOURNAL = {Oncology Research},
VOLUME = {33},
YEAR = {2025},
NUMBER = {7},
PAGES = {1511--1530},
URL = {http://www.techscience.com/or/v33n7/62629},
ISSN = {1555-3906},
ABSTRACT = {
Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy.},
DOI = {10.32604/or.2025.061120}
}